# Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma

Source: https://onco.cc/trials/nct04443010/  
OnCo record `nct04443010` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Temozolomide in glioma & glioblastoma, run by Philogen S.p.A., now recruiting.

## Summary

Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma is a phase 1/2 interventional study registered as NCT04443010 by Philogen S.p.A., with 226 participants planned, started 2021-01-20 and due to reach its primary completion in 2026-10. Interventions recorded: Onfekafusp alfa and Temozolomide.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04443010
- Phase: 1/2
- Setting: A Study to Evaluate the Safety and Efficacy of the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF Plus Standard Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma
- Sponsor: Philogen S.p.A.
- Enrolled: 226

## Sources

- ClinicalTrials.gov NCT04443010: https://clinicaltrials.gov/study/NCT04443010

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [Temozolomide](https://onco.cc/drugs/temozolomide/)
- companies: [Philogen S.p.A.](https://onco.cc/companies/philogen-s-p-a/)

---
JSON: https://onco.cc/api/v1/entities/nct04443010.json